MedTrace Logo

Effect of Omeprazole on Pharmacokinetics of SHR2554 in Healthy Subjects

NCT06093945 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-12-05

No results posted yet for this study

Summary

The study aimed to assess the effects of omeprazole on single-dose SHR2554 in healthy subjects, exploring the pharmacokinetic changes of SHR2554 and ensuring the safety when SHR2554 is co-administered with omeprazole.

Conditions

  • Malignant Tumor

Interventions

DRUG

SHR2554 tablet dosing

SHR2554 350mg taken on Day 1 and Day 10

DRUG

Omeprazole tablet dosing

Omeprazole taken from Days 5 to Day 10

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-11-06
Primary Completion
2023-11-29
Completion
2023-11-29

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06093945 on ClinicalTrials.gov